Biotech Values

[DewDiligence]

ANDS CC:

ANDS’ CEO said he will be pleased if ANA975 monotherapy reduces HCV viral load by a mere 1.0 logs. That’s because (as noted in #msg-10929237) an immunomodulator cannot by itself be expected to eradicate chronic HCV. Whether or not ANA975 is successful at replacing interferon, direct viral inhibitors (a protease inhibitor, a polymerase inhibitor, or both) will still be needed. (Also see #msg-10932176.)